CAR T-cell therapy found highly effective in patients with high-risk non-Hodgkin lymphoma

(Dana-Farber Cancer Institute) A CAR T-cell therapy known as axicabtagene ciloleucel (axi-cel) drove cancer cells to undetectable levels in nearly 80% of patients with advanced non-Hodgkin lymphoma (NHL) in a phase 2 clinical trial, Dana-Farber Cancer Institute investigators report at the virtual 62nd American Society of Hematology (ASH) Annual Meeting.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news